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Abstract  Amyotrophic lateral sclerosis ゅALSょ is an incurable and terminal disease which causes progressive symptoms that negatively impact on quality of life┻ The aim of ALS care is to minimise morbidity and maximise quality of life┻  This review describes the current approaches to supportive care and outlines the evidence for these strategies┻  Recent changes Supportive care for patients with ALS by a specialist multidisciplinary team is associated with improved survival┻  Respiratory support using non┽invasive ventilation can improve survival and sustain quality of life┸ however the role of diaphragmatic pacing is less clear with several studies reporting reduced survival with its use┻  There is building evidence of the key role of metabolic dysfunction in the pathogenesis of ALS and that interventions that optimise nutrition may improve quality of life and survival┻ Cognitive changes are now recognised to occur commonly in ALS and impact on prognosis┻ (ow best to intervene and support patients and carers when cognitive changes occur is yet to be established┻ There is increasing recognition of the need for specialist palliative care to provide support for those facing complex and distressing problems throughout the disease course as well as for those approaching the end of life┻  Future research The basis of supportive management is moving from guidelines based on expert consensus towards an evidence┽based approach┻  This will encourage the use of effective treatments and could reduce the risk of harm caused by ineffective or unsafe interventions┻   
 ね
Key points 
• The aim of the management of ALS is to maximise quality of life and minimise morbidity┻ 
• Guidelines for symptomatic care are becoming more evidenced┽based┻ 
• Management by specialist clinic based multidisciplinary team is associated with improved survival┻ 
• Non┽invasive ventilation improves survival and quality of life in patients with respiratory failure┻ 
• Nutrition is an independent indicator of survival and early insertion of a gastrostomy is recommended prior to significant weight loss┻ 
• Cognitive impairment is common in ALS and is associated with a worse prognosis┹ optimal management of this problem is unclear┻    
Introduction  Amyotrophic lateral sclerosis ゅALSょ is a progressive┸ incurable disease causing muscle weakness and paralysis┻  Whilst the lifetime incidence of ALS is な in ねどど┸ average survival is only two to four years from onset┸ meaning prevalence is low ゅapproximately の┻ね per などど どどどょ な┸に┻  The extensive search for a disease modifying therapy has been unrewarding┸ with riluzole being the only drug shown to offer a small survival benefit of approximately three months ぬ┸ね┻   There is an increasing recognition of the impact symptoms of ALS have on patients and their families┻  As a result┸ the focus of ALS management has shifted towards specialist multidisciplinary care which provides holistic support aiming to minimise morbidity and maximise function and quality of life の┽など┻   )n the last two decades┸ major guidelines focussing on supportive care have been developed なな┽なね┻  (owever┸ in the absence of evidence┸ recommendations have largely been based on consensus or expert opinion and individual clinicians╆ practise varied┻ This review will discuss the evidence underpinning the approach to supportive care in ALS and priorities for future research┻  ゅTable なょ 
 
Organisation of care 
 The management of patients with ALS care is often led by a multidisciplinary team of specialists working together to provide a rapid and sensitive diagnosis followed by holistic care throughout the disease ゅBox なょ┻   Attendance at a multidisciplinary clinic is associated with improved survival┸ independent of the use of non┽invasive ventilation┸ riluzole and gastrostomy feeding の┸など┸なの┸なは┻ The cause of this additional survival benefit is unknown and is worthy of further study┸ particularly as it appears that the structure in which care is delivered impacts on patient survival┻  This was demonstrated in a study comparing models of care in )reland and Northern )reland┻  Centralised multidisciplinary hospital clinic based care was associated with superior outcomes compared to either attending a general neurology clinic with no integrated care or receiving co┽ordinated care through a community care network など┻  The reasons behind these differences are unclear┸ but the survival benefits may relate┸ in part┸ to the complex decision┽making processes that can take place within the team in the 
 の
centralised clinic setting など┻  Attendance at a multidisciplinary clinic may reduce and shorten hospital admissions and patients are more likely to use riluzole┸ assistive aids and non┽invasive ventilation but the impact on quality of life is less clear は┸ば┸など┸なば┻   Patients value the convenience and quality of unified care but whilst single appointments reduce travel time to multiple specialists┸ travelling to hospital and the prolonged nature of appointments remains a problem ぱ┸なぱ┻  Alternative services such as using telemedicine or remote monitoring may be useful to sustain access to specialists throughout the disease without the need to travel なひ┻ )t will however┸ be essential to ensure that the beneficial aspects of traditional clinic based multidisciplinary care are incorporated into these new models of service┻  Box な┺ The components of a multidisciplinary team┻ The core team members listed have been compiled from those listed in studies evaluating multidisciplinary care in ALS の┽など┻ 
 
Components of a multidisciplinary ALS team:Neurologist 【rehabilitation physicianNurse 【 care coordinator Physiotherapy Occupational therapy Respiratory specialist Speech therapy Dietician  Charity worker  Social worker 【 benefits advisor Neuropsychology 【 Psychiatry  
Other specialists that may be required:Gastrostomy services Palliative care 【 hospice services Assistive technology Wheelchair services Augmentative and Alternative Communication services Continence team 
In liaison with: General practitioner Community ｇoutreach teamｇ (ospice 【 hospital at home service
   
 は
Management of respiratory function 
 Type two respiratory failure is the most common cause of death in ALS and non┽invasive ventilation was the first intervention shown to have a positive impact on both survival and quality of life にど┻ Symptoms of respiratory failure can develop insidiously and initially respiratory failure may only occur in REM sleep┸ when diaphragmatic weakness causes hypoxia and hypercapnoea resulting in sleep disturbance ゅTable にょ┻  Later in the disease┸ patients develop dyspnoea at rest┸ poor cough and respiratory tract infections┻  These problems are exacerbated by bulbar dysfunction┻  Early trials of drugs that may improve respiratory muscle contractile force and cough effectiveness are underway にな┸にに┻  
Monitoring of respiratory failure The best strategy for monitoring and identifying respiratory failure is unclear┻  Expert guidelines recommend regular monitoring of respiratory function at least every three months┸ by enquiring about symptoms of respiratory failure and using objective measures なな┸なぬ┸なね┻  Despite this guidance┸ in some clinics access to objective measures of respiratory muscle strength is limited and these measurements may be insensitive to respiratory failure and unsuitable for patients with bulbar or cognitive dysfunction にぬ┻ The most basic objective measure advised is daytime oxygen saturations plus either forced vital capacity or sniff┽nasal┽inspiratory pressure ゅBox にょ┻  )f a patient exhibits signs or symptoms of respiratory failure it is recommended that they undergo arterial or capillary blood gas analysis┻  )t should be noted that oxygen desaturation usually occurs late in type )) respiratory failure and daytime measurements of arterial carbon dioxide may not be a reflection of overnight function にど┻ Therefore if respiratory failure is suspected and daytime gas analysis is normal then nocturnal oximetry studies should be conducted なね┸にね┻ Non┽invasive transcutaneous measurement of carbon dioxide levels is now possible and this can supplement the information from overnight oximetry にの┻      
 ば
Box に┺ The objective indicators of respiratory failure┻  
Objective indicators of respiratory failure Forced vital capacity ジ のどガ Forced vital capacity ジ ぱどガ ギ symptoms of respiratory failureSN)P or M)P ジ ねど cm(にO  SN)P or M)P ジ はの cm(にO ゅmenょ or のの cm(にO ゅwomenょ ギ symptoms of respiratory failure Repeated tests show a rate of decrease of SN)P or M)P スなど cm(にO per ぬ months  Daytime arterial COに ofジはkPa with symptoms of respiratory failureDaytime arterial COに of スはkPa Daytime Oに saturations of ジひねガ Nocturnal episodes of hypercapnoeaNocturnal episodes of hypoxia SN)P┺ sniff nasal inspiratory pressure┸ M)P┺ mouth inspiratory pressure  Adapted from The use of non-invasive ventilation in the management of motor neurone disease┸ National )nstitute for Clinical Excellence guidelines┻ N)CE clinical guideline などの ゅにどなどょ なね┻   
Non-invasive ventilation A randomised controlled trial of patients with ALS using non┽invasive ventilation ゅN)Vょ demonstrated survival and quality of life benefits にど┻ ゅFigure なょ Using N)V initially at night and also if required┸ in the daytime┸ was associated with a median survival gain of seven months and quality of life was improved and sustained throughout the trial┻   Using N)V can be challenging┸ requiring perseverance by patients and carers as well as significant support from specialists には┸にば┻  Unsurprisingly those with poor adherence or poor ventilation fail to gain survival benefit にぱ┻ Patients in the original trial with poor bulbar function failed to experience a survival benefit but did experience improvement in quality of life にど┻  Current guidance recommends that a trial of N)V should be offered to patients even if they may not be able to tolerate N)V because they may experience an improvement in sleep┽related symptoms なね┻  This approach is supported by a recently published cohort study of にひに patients that suggested that patients with bulbar onset disease may┸ in fact┸ gain survival benefit from using N)V にひ┻  Additional equipment such as humidification and alternative masks may promote adherence by dealing with problems such as dry mouth┸ claustrophobia and difficulties eating┻  Battery packs and back┽up ventilators reduce the burden on routine life and allow patients to travel ぬど┻  Face┽to┽face training can be supplemented by online resources such as ╉MyN)V╊ ゅwww┻mymnd┻org┻ukょ┸ which promotes the benefits of N)V use and encourages adherence ぬな┻  
Invasive ventilation The number of patients undergoing tracheostomy ventilation is increasing but varies from country to country ぬに┸ぬぬ┻  Patients may commence invasive ventilation in a desire to prolong life┸ when they are unable to tolerate N)V┸ to manage respiratory secretions or in an emergency following a respiratory crisis ぬぬ┻  One cohort study did suggest however┸ that invasive ventilation offers no survival advantage for patients aged over はど years ぬに┻  )nvasive ventilation is limited by 
 ぱ
resources and concerns that the patient and carer quality of life may be poor or that patients may become ╉locked┽in╊┸ losing the ability to communicate ぬね┻  )t is good practice to discuss respiratory failure┸ potential treatments and end┽of┽life options early and throughout the disease so that individual wishes are known should an unpredicted respiratory emergency occur なね┻ 
 
Respiratory and oropharyngeal secretions Dysphagia and poor cough cause excessive oropharyngeal and respiratory secretions┸ occurring in approximately half of patients attending ALS clinics ぬの┻ Excessive secretions cause social embarrassment┸ increase the risk of aspiration and pneumonia┸ and can impair the use of N)V┻  Management varies and drug treatments are often ineffective┸ with half of those experiencing the problem having uncontrolled symptoms ぬの┻  The treatment of thin saliva can dry the mouth and thicken secretions┸ making their clearance more difficult┻ )ntraglandular botulinum toxin was effective in reducing secretions in a randomised controlled trial of にど patients and may reduce aspiration ぬは┻  Botulinum toxin is well tolerated and its effectiveness may be improved by using ultrasound┽guidance ぬは┽ぬぱ┻  )t can cause drying of the mouth and can ゅrarelyょ worsen dysphagia and therefore it tends to be reserved for those with a gastrostomy ぬの┸ぬば┸ぬひ┻  Radiotherapy is effective but is limited by availability and risk of permanent dry mouth ねど┸ねな┻  There are no studies examining the drug treatment of respiratory secretions but mucolytics such as carbocysteine and airway humidification using N)V or nebulised saline are recommended なぬ┸なね┻  
Cough augmentation  Dysphagia and respiratory muscle weakness leads to weakened cough and poor secretion clearance┸ increasing the risk of respiratory infections┻  Monitoring cough effectiveness using measures such as peak cough flow may identify patients at risk of ineffective sputum clearance ねに┸ねぬ┻  )mproving lung recruitment and thereby increasing peak cough flow and sputum clearance may be achieved by using N)V┸ breathing exercises ゅe┻g┻ ╉breath┽stacking╊ょ or a lung volume recruitment bag ねね┸ねの ゅFigure ぬょ┻  Mechanical insufflation┽exsufflation devices ゅe┻g┻ Cough Assistょ are more effective in increasing peak cough flow but are difficult to use in those with poor bulbar function ねの┻ External high frequency chest wall oscillation using a wearable vest may also improve sputum clearance ねは┻  Cough assist use is recommended during acute infective episodes but trials to determine the benefits of regular prophylactic use of cough augmentation devices are awaited┻  
Diaphragmatic pacing  )n にどなな┸ the United States Food and Drug Administration gave approval for use of a diaphragmatic pacing device in patients with ALS under the (umanitarian Device Exemption program ねば┻  The approval was based on partially published data from a non┽randomised uncontrolled cohort of ぱは patients with ALS┸ which reported a positive impact of diaphragmatic pacing on survival and sleep quality┻ (owever┸ in にどなね┸ a randomised controlled trial of diaphragmatic pacing in the UK found patients using pacing survived on average┸ なな months less than who did not undergo pacing ねぱ┻  A French study was also terminated early following findings of excess mortality in those who underwent pacing ねひ┻  A US study has 
 ひ
suspended recruitment whilst the implications of the conflicting results are explored┸ and a post marketing approval registry study continues のど┸のな┻ )t may be possible to pool the data from these trials to determine whether there is a role for pacing in a particular sub┽group of patients┸ however for the majority this would appear not to be the case┻   At present it is recommended that diaphragm pacing is only used within the context of clinical trials ねぱ┻    
 
Nutrition and swallowing  Malnutrition and weight loss are well recognised poor prognostic factors in ALS のに┽のの┻ Reasons for weight loss are multifactorial and include muscle wasting secondary to denervation┸ poor oral intake due to dysphagia┸ upper┽limb weakness and poor appetite and energy intake is lower than predicted daily requirements のは┻  Calorie ingestion of less than the recommended daily amount has been observed in ばどガ and ひねガ of patients with ALS in two cohorts のば┸のぱ┻ Low oral intake is compounded by an increased resting energy expenditure which occurs in up to はばガ of patients with ALS のに┸のは┸のひ┽はな┻  The cause of hypermetabolism in ALS is unknown┸ with several unproven hypotheses including mitochondrial dysfunction はに┻ Given the high prevalence of hypermetabolism and the association of weight loss and malnutrition with a poor prognosis in ALS┸ a small pilot study of high calorie diets in gastrostomy fed patients with advanced disease has been undertaken はぬ┻ The results indicated a possible survival advantage with good tolerability of high calorie supplementation┻  This demonstrated the potential of a high calorie nutritional intervention to influence the disease course in ALS┻ Whilst the approach in this study has the advantage of controlling the nutritional intake accurately through a gastrostomy tube┸ the main draw back is that patients are receiving the nutritional intervention late on in the disease course┻   )t is recommended that patients undergo regular assessment of swallow and weight┸ and receive advice regarding diet and swallowing techniques なぬ┻  Exercises to improve cough and swallow and even insertion of autologous myoblasts into the tongue are being explored はね┽はは┻  An observational study injecting botulinum toxin into the upper oesophageal sphincter in にど patients reduced signs of aspiration but further trials are awaited はば┻ 
Gastrostomy feeding Enteral feeding is commonly used to sustain intake of nutrition and medication but there is no convincing evidence that it improves survival┸ nutritional outcomes or quality of life はぱ┻  Given it is already extensively used in ALS┸ it is unlikely that a randomised controlled trial with a placebo arm to definitively explore this issue would be possible┻  (owever┸ evidence regarding the timing and method of gastrostomy have become clearer following a prospective cohort study of ぬねの patients undergoing gastrostomy insertion はひ┻  Whilst expert consensus previously recommended that a loss of などガ of body weight should trigger insertion┸ this cohort study suggested that this may be too late なな┻  Those patients undergoing the procedure who had already lost more than のガ of their premorbid weight were unlikely to regain this weight with enteral feeding はひ┻  )t 
 など
is therefore recommended that patients should be referred to a dietician and speech therapist at the onset of dysphagia and consider gastrostomy insertion early in the disease┸ ideally prior to the development of respiratory failure or significant weight loss なぬ┸はひ┻   )dentifying the correct time for an individual to undergo the procedure is challenging and patients often chose to delay insertion┸ particularly those still enjoying the taste and the social importance of eating ばど┸ばな┻ Patients may view gastrostomy negatively┸ as it represents an important milestone in their disease and using a gastrostomy also places a major burden on carers ばど┸ばに┻  For some patients with severe cognitive impairment or who are frail or nearing the end of life┸ conservative management may be more appropriate┻ Alternatives such as nasogastric feeding┸ subcutaneous fluids or even parental nutrition may be considered なぬ┻   The technique for gastrostomy insertion depends on a patient╆s respiratory function and available expertise┻   Endoscopic placement of a percutaneous gastrostomy ゅPEGょ is appropriate for patients without respiratory failure who can tolerate sedation┻   For those with respiratory failure┸ radiological guided gastrostomy ゅR)Gょ avoids the need for sedation but the balloon┽retained tubes are significantly more likely to become displaced┸ leak or require replacement いばどう┻  Per┽oral image┽guided gastrostomy ゅP)Gょ can be performed whilst using non┽invasive ventilation┻  This involves inserting a nasogastric tube as a guide allowing a robust PEG gastrostomy tube to be pulled through and out of the abdominal wall いばどう┻  All three methods appear to be as safe as each other はひ┻   Patients may develop bloating or bowel disturbance following initiation of enteral feeding┻  Adjustment in feed regime may be helpful but there is no evidence to support any specific approach┻   
Musculoskeletal symptoms 
 
Spasticity Spasticity causes pain and loss of function and can be exacerbated by factors such as infection and poor positioning┻ There is no evidence to recommend one management strategy over another ばぬ┻  Muscle relaxants can exacerbate muscle weakness and their sedating side┽effects are often intolerable┻  One randomised controlled trial of prescribed exercise in にの patients observed small improvements in disability and spasticity ばね┻  )n observational studies┸ intrathecal baclofen improved symptoms and quality of life in patients where oral medication has failed ばの┸ばは┻   
Cramps Cramps are common in ALS but Cochrane review of trials of various treatments including one randomised controlled trial of tetrahydrocannabinol┸ reported no evidence to recommend any particular treatment ばば┸ばぱ┻  An open label study of levetirecetam in にど patients has reported a reduction in cramp frequency and severity ばひ┻  Quinine is the most commonly used therapy for cramps but use for 
 なな
this indication is restricted in the United States because of reports of rare but serious haematological and cardiac events ゅははの serious events and ひぬ deaths between なひはひ and にどどはょ ぱど┻   A Cochrane review of quinine in patients with various causes of cramp found moderate evidence that quinine was safe and effective ぱな┻  The side effects of quinine are dose dependent and it is possible that low dose quinine used in cramps may not be associated with these side┽effects but the studies included in the review may be too small to detect very rare events ぱな┻ )n the absence of an effective alternative┸ guidance from the American Academy of Neurology recommends that quinine only be used as a last resort なな┻  
 
Pain More than half of those with ALS experience pain and it impacts on quality of life┸ and a small number experience other sensory symptoms but no trials in ALS have been conducted ぱに┸ぱぬ┻   
Psychological symptoms  The incidence of depression ranges from ななガ ゅinterview studiesょ to ばのガ ゅself┽reported measuresょ and is associated with a poorer quality of life┻  There have been no trials of specific ALS treatments┸ so standard therapies ゅselective┽serotonin reuptake inhibitors┸ amitriptyline or mirtazapineょ are recommended なぬ┻    There is increasing recognition of the overlap between ALS and other neurodegenerative diseases┸ in particular┸ frontotemporal dementia and Parkinsonism┹ both in the same patient┸ or within their family┻  Some of these patients have pathogenic mutations┸ the most common being the recently identified abnormally┽long hexonucleotide repeat expansion CひORFばに ぱね┽ぱは┻ Approximately など┽なのガ of ALS patients will show signs of frontotemporal dementia┹ typically frontal variant with executive dysfunction┸ language or behaviour change ぱば┻   A further のどガ experience mild cognitive or behavioural change┻ Patients with executive dysfunction have a poorer prognosis┸ whilst behavioural change has a negative impact on carer quality of life ぱば┸ぱぱ┻  An ALS specific tool ゅthe Edinburgh Cognitive Behavioural ALS Screen toolょ has been developed which can identify frontotemporal deficits ぱひ┻  Whilst treatment is not available┸ early recognition allows the provision of support and coping strategies for patients and carers┸ and facilitates decision making and advanced planning┻  Approximately half of patients experience emotional lability┸ pathological laughter or crying and this is more common in those with bulbar onset ALS ひど┻  A selective┽serotonin reuptake inhibitor ゅfluvoxamineょ and amitriptyline have been associated with reduced emotional outbursts in small observational studies ひな┸ひに┻  More recently┸ two randomised controlled trials of Nuedexta ゅa combination of dextromethorphan and quinidineょ including ぬぬぬ patients with ALS found a significant reduction in emotional events ひぬ┸ひね┻  Side effects include dizziness and somnolence┸ which led to にねガ of patients to stop taking the drug in one study┻  Nuedexta should be avoided in those with a risk of cardiac arrhythmia as it can prolong the QT interval┻  )t is licensed for use in the United States and is awaiting European license┻ 
 なに
 )nsomnia and fatigue are common and impact on quality of life ひの┸ひは┻   )n one small study modafinil was found to improve symptoms of fatigue but larger studies are required ひば┻  There have been no studies of interventions for insomnia and therefore standard treatments ゅhypnotics┸ mirtazapine and amitrityplineょ are recommended なぬ┻  




 Assistive devices can improve function and independence but need to be accessible┸ affordable and appropriate for the changing needs of patients┻  By working directly with patients and clinicians┸ specifications for devices to meet the needs of patients with ALS can be established┻  Two recent solutions have demonstrated the benefit of these collaborations┺ the Sheffield Support Snood and Powered Neuro Wheelchairs ひひ┸などど┻   Neck weakness causes head drop┹ which leads to pain and can exacerbate problems with communication┸ eating and drooling┻   Current neck collars were described as being too rigid and restricting movement┸ or too soft┹ providing ineffective support ひひ┻ The Sheffield Support Snood was developed in a collaboration involving clinicians┸ patients and engineers┻ )t offers an adaptable structure which can provide tailored support to an individual that is modified as needs change┻  ゅPicture ねょ  Early evaluation suggests it provides good support without restricting movement┸ eating or speaking and for most patients was preferable to their previous collar などな┻  Using a powered wheelchair improves mobility┸ independence and quality of life but there is a lack of evidence to determine the appropriate specification for patients with ALS などに┸などぬ┻  Selection of the appropriate chair relies on the expertise of the therapist and choice may be limited by cost and availability┻ A collaboration of patients and therapist in the UK┸ working with wheelchair manufacturers developed three ╉Powered Neurochairs╊ などど┻  Each offers high specification at an optimum┸ affordable cost so patients can quickly access a wheelchair that will meet their needs┻  
Communication  For patients with dysarthria there are many augmentative assistive communication solutions available┻ These include simple writing boards┸ text┽to┽speech apps and eye┽gaze systems┻  Voice banking is a relatively new option that can provide a more natural voice to patients who use text┽to┽speech apps such as 
 なぬ
╉Predictable╊ などね┻  Patients can use software such as Model Talker to record their own voice although the quality of the synthesised voice relies on patients recording なはどど phrases┸ which is time consuming などの┻  Patients can adopt a ╉donated╊ voice and voice banks are now able to combine multiple voices to provide an individual voice matched to age┸ sex and accent┻  There is some way to go before communication devices are fast enough to maintain a conversation and produce a voice that can match the prosody of natural speech などは┻  )n the future brain┽computer interfaces may allow patients with severe disability to communicate using electroencephalogram ゅEEGょ control┻  Currently this technology has been evaluated in only a small number of patients┸ mostly in experimental environments and is limited by the usability and reliability of the technology などば┻ 
 
Care at the end of life   The experience at the end of life can have a significant impact on patients and their families などぱ┽ななど┻  Due to the complexities of management of advanced ALS it is recommended that specialist palliative care services are involved early and throughout the disease ななな┻  Advanced care planning allows patients and their families to document their attitudes towards future events but enactment of these wishes may not always be straightforward and decisions should be reviewed regularly ななに┻  Anticipatory prescribing of medications to treat symptoms at the end of life may enable informal carers to administer medication whilst subcutaneous infusions may be required for on┽going symptoms ゅTable ぬょ┻ The Motor Neurone Disease Association has developed a ╉Just┽in┽case╊ box in which medication for carers or clinicians ゅe┻g┻ ambulance service or nursesょ to use to treat terminal symptoms can be stored and recorded ななぬ┻    
Withdrawal of ventilation With progression of respiratory muscle weakness┸ it is common for individuals to begin to use N)V during the day for symptom relief┻  At the end of life┸ some patients die peacefully with N)V in┽situ whilst others simply stop using it without experiencing significant difficulties などひ┻  )n a proportion of patients the decision to no longer continue using N)V is more complex┻  Patients may require the assistance of others┸ for example┸ to remove the mask┸ and may require treatment to prevent distressing symptoms┻  This can cause anxiety on legal and ethical grounds which may interfere with the delivery of the best end┽of┽life care ななな┸ななね┻ The law in many countries recognises that a patient with capacity can opt to refuse or withdraw from medical treatment even if it will result in death┻    Guidelines have been drawn up to advise those considering ventilation withdrawal ななな┸ななね┻   )t is recommended that patients┸ family and clinicians openly discuss their thoughts about ventilation and the circumstances at the end┽of┽life┻  These discussions should begin before ventilation commences and continue throughout the illness and may be triggered by situations such as when patients begin to use ventilation in the day to relieve dyspnoea or if topics such as advanced decision┽making or euthanasia are raised┻  )f a patient expresses a wish to withdraw from ventilation the patient╆s capacity must be assessed and it must be established that the decision is the settled position of the individual┻  
 なね
Conscious sedation ゅi┻e┻ drowsy but awakeょ using opiates and benzodiazepines should be achieved prior to ventilation withdrawal to avoid distressing symptoms┻ Deep unconscious sedation may be needed to tolerate withdrawal in those who become breathless quickly after mask removal┻ Although patients may die quickly┸ preparations must be made to support patients where the process may take longer ななね┻  
 
Future research and the need to develop the evidence base for 
symptomatic care 
 Given the clear evidence of benefit of non┽invasive ventilation┸ other interventions to managed the consequences of respiratory failure may also improve survival and quality of life┻ The most important question is whether cough augmentation can reduce the incidence of respiratory infection┻  Other areas of uncertainty include how to monitor respiratory function┸ how to improve the tolerance and effectiveness of N)V and the management of oropharyngeal secretions┻ Focus is also needed to determine the optimum approach to nutrition┸ pre┽ and post┽ gastrostomy and to improve other distressing symptoms that have an impact on quality of life┻  )t will also be important to develop an understanding of the key aspects of multidisciplinary care that improve survival and how these benefits can be delivered to all patients┻ Like many of the other interventions described in this review┸ multidisciplinary care has multiple components┸ each of which may influence the outcome of the intervention┻  Establishing the aspects of the intervention that are key to its success┸ in whom they are successful and how they can be delivered will be challenging ななの┻   Previous guidelines have provided an excellent benchmark for standards of ALS care but in lieu of much high quality evidence┸ these standards have understandably been largely based on expert and consensus opinion┻  Developing an evidence base for symptomatic case is important because┸ whilst improvements have been made over the last decade┸ access to standard treatments that have been proven to be beneficial remains variable┻  For example┸ despite clear evidence to support the use of riluzole┸ patients attending a non┽specialist clinic remain less likely to be receive the drug など┻  Prior to the randomised controlled trial of N)V few patients in the UK were using it ななは┻  Following this trial and subsequent publication of National )nsitute for Clinical Excellence ゅN)CEょ guidelines in にどなど in the UK┸ N)V use has markedly increased にぬ┻ Specialist clinics will promote the use of N)V┸ but in some areas there still remains a lack of access to monitoring and treatment as well as inequalities in use in some patient groups にぬ┻   Promoting evidence┽based guidelines should reduce the potential for patients who feel they have little to lose to be harmed by using unsafe┸ untested treatments┻ For example┸ prior to the recent research demonstrating its potential harm when used in a non┽selective manner┸ diaphragmatic pacing systems were already being widely implanted around the world┻ This story has several lessons for the ALS community┻ The most important is that all interventions should be 
 なの
evaluated thoroughly and usually this will be in the context of a randomised controlled study┻   The arguments that patients with ALS have nothing to lose and that they have a right to try untested therapies are understandable┸ given the poor prognosis and the lack of curative treatments ななば┸ななぱ┻  (owever┸ such approaches can lead to patient harm and become a barrier to the development and evaluation of effective therapies┻   
Conclusion  Current evidence indicates that supportive care for patients with ALS is best delivered by a specialist multidisciplinary team┸ which can provide holistic care to patients┸ family and carers maximising function and quality of life┻  Further work is needed to strengthen the evidence base for the management of ALS┸ which ultimately should ensure universal good practice and reduce inequalities in care┻    Figure な┺ A non┽invasive ventilation mask ゅcopyright Sheffield )nstitute for Translational Neurosciencesょ Figure に┺ An online guide for people with ALS using non┽invasive ventilation┻  www┻mymnd┻org┻uk ゅcopyright Sheffield )nstitute for Translational Neurosciencesょ Figure ぬ┺ A lung recruitment ╉breath┽stacking╊ device ゅcopyright Sheffield )nstitute for Translational Neurosciences Figure ね┺ The Sheffield Support Snood ゅcopyright Sheffield )nstitute for Translational Neurosciencesょ   Table な┺ The management of common symptoms in ALS┻  Table に┺ The symptoms and signs of respiratory failure┻  Table ぬ┺ The management of symptoms at the end of life┻      
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Carbocysteine Nebulised saline Grade DGrade D Cough augmentationHumidification of NIV Suction Reduction in dairy product intake 




Hyoscine patches Amitriptyline Atropine drops Glycopyrrolate Botulinum toxin ぬは 
Grade D Grade D Grade D None Grade B 
Radiotherapy ねど┸ ねな Pineapple juice Suction  
Grade C None Grade D 
Dry mouth Artificial saliva sprays【tablets None Humidification of NIV None 
 Saliva stimulating tablets None    
Cramps Quinine ばば┸ ぱな Levetiracetam ばひ Grade B Grade C Physical therapy【exercise Grade D 
Spasticity Baclofen【 tizanidine 【 dantrolene Grade D Prescribed exercise ばね Hydrotherapy Grade B  Grade D  BenzodiazepinesIntrathecal baclofen ばの┸ ばは Grade DGrade C Cryotherapy Grade D 
Emotional 
lability 
SSRIs ひな Dextromethorphan 【 quinidine ひぬ┸ ひね Amitriptyline ひに 
Grade C Grade A  Grade C 
 
Depression SSRIs Grade D   
Anxiety Benzodiazepines Grade D  
Fatigue Modafinil ひば Grade B    SSRIs┺ selective serotonin re┽uptake inhibitors┸ DM┺ dextromethoprhane┸ Q┺ quinidine┸ NIV┺ non┽invasive ventilation Grading of recommendation proposed by the Oxford Centre for Evidenced┽based Medicine┸ にどどひ  www┻cebm┻net【oxford┽centre┽evidence┽based┽medicine┽levels┽evidence┽march┽にどどひ【 Grade A┺ systematic review or individual RCT with narrow confidence interval┻   Grade B includes systematic reviews or cohort or case┽control studies or extrapolationsこ of level A studies Grade C┺ case┽series or poor quality cohort studies or extrapolationsこ of level A or B evidence Grade D┺ expert opinion or inconsistent research from level A┸ B or C evidence こextrapolations are where data is used in a situation that has potentially clinically important differences from the original study situation    
 
Table に┺ The symptoms and signs of respiratory failure┻   
Symptoms of respiratory failure Signs of respiratory failureBreathlessness )ncreased respiratory rateOrthopnoea Shallow breathingRecurrent chest infections  Weak coughDisturbed 【 un┽refreshing sleep Weak sniff Nightmares Abdominal paradox ゅinward movement of the abdomen during inspirationょ  Daytime sleepiness Poor concentration Use of accessory muscles of respiration Poor memory【confusion Reduced chest expansion on maximal inspiration (allucinations Morning headaches Fatigue Poor appetite  Cough Excessive respiratory secretions Adapted from The use of non-invasive ventilation in the management of motor neurone disease┸ National )nstitute for Clinical Excellence guidelines┻ N)CE clinical guideline などの ゅにどなどょなね┻  
Table ぬ┺ The management of symptoms at the end┽of┽life┻    
Terminal 
symptoms 




Dyspnoea Opiates Benzodiazepines Morphine の┽などmg po【PEG【sc Fans 【 cool compresses 
  Diamorphine に┻のmg s【c Non┽invasive ventilation 
Laryngospasm 
/ choking 
Benzodiazepines Lorazepam ど┻のmg po【PEG Non┽invasive ventilation 
  Midazolam に┻のmg s【c Suction
Respiratory 
secretions 
(yoscine butylbromide Glycopyrronium (yoscine butylbromide にどmg s【c Cough┽augmentation devices Suction 
Terminal 
agitation 
Benzodiazepines Lorazepam ど┻のmg po【PEG Midazolam に┻のmg s【c 
Pain Drug choice depends on cause Morphine の┽などmg po【PEG【sc Transdermal opiate patch 
Nausea / 
vomiting 
(yoscine butylbromide (yoscine butylbromide にどmg s【c 
Ventilation 
withdrawal 
Opiates Benzodiapepines Morphine などmg s【cMidazolam などmg s【c Continuous s【c infusion po┺ per oral┸ PEG┺ via gastrostomy┸ s【c┺ subcutaneous Based on National )nstitute of Clinical Excellence N)CE guidelines NGぬな ゅCare of dying adults in the last days of lifeょ┸ APM position on Withdrawal of Ventilatory Support for Respiratory Failure at the Request of an Adult Patient なな and Pathway for Preparing to Withdraw Non┽)nvasive Ventilation ゅN)Vょ in Patients with MND なね┻ 




